Stockreport

Barinthus Bio Initiates Phase 1 Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Barinthus Biotherapeutics plc - American Depositary Shares  (BRNS) 
PDF Investigational immunotherapy candidate, VTP-1000, seeks to address significant unmet need in people with celiac disease.An estimated one in 100 people globally suffer f [Read more]